Abstract
Drug allergies are heterogeneous and multifactorial diseases and are always the consequence of an exaggerated immune-mediated reaction. Previously described models of immunologic mechanisms (mainly based on Gell and Combs classification) cannot fully explain the physiopathology of these diseases; it seems therefore important to identify risk factors. Clinical and biologic tests are helpful diagnostic tools but are limited in their sensitivity and reliability and are certainly not predictive. Epidemiologic data supply information concerning the prevalence of drug hypersensitivity: female gender, concomitant infections (HIV, herpes) and concurrent illnesses (systemic lupus erythematosus) are all significant risk factors. Another host-related factor is the genetic predisposition of patients and is currently under investigation in our laboratory. Most genetic studies concern HLA haplotype association or polymorphism in genes encoding drugmetabolising enzymes. A current study by our group seems to implicate polymorphisms within the promoter of IL-10, a cytokine with anti-inflammatory properties. The chemical properties of the drug and the treatment regimen also influence the development of drug allergies.
Keywords: Drug allergies, risk factors, β-lactam allergy, SNP
Current Pharmaceutical Design
Title: Drug Hypersensitivity: Epidemiology and Risk Factors
Volume: 12 Issue: 26
Author(s): L. Guglielmi, P. Guglielmi and P. Demoly
Affiliation:
Keywords: Drug allergies, risk factors, β-lactam allergy, SNP
Abstract: Drug allergies are heterogeneous and multifactorial diseases and are always the consequence of an exaggerated immune-mediated reaction. Previously described models of immunologic mechanisms (mainly based on Gell and Combs classification) cannot fully explain the physiopathology of these diseases; it seems therefore important to identify risk factors. Clinical and biologic tests are helpful diagnostic tools but are limited in their sensitivity and reliability and are certainly not predictive. Epidemiologic data supply information concerning the prevalence of drug hypersensitivity: female gender, concomitant infections (HIV, herpes) and concurrent illnesses (systemic lupus erythematosus) are all significant risk factors. Another host-related factor is the genetic predisposition of patients and is currently under investigation in our laboratory. Most genetic studies concern HLA haplotype association or polymorphism in genes encoding drugmetabolising enzymes. A current study by our group seems to implicate polymorphisms within the promoter of IL-10, a cytokine with anti-inflammatory properties. The chemical properties of the drug and the treatment regimen also influence the development of drug allergies.
Export Options
About this article
Cite this article as:
Guglielmi L., Guglielmi P. and Demoly P., Drug Hypersensitivity: Epidemiology and Risk Factors, Current Pharmaceutical Design 2006; 12 (26) . https://dx.doi.org/10.2174/138161206778194088
DOI https://dx.doi.org/10.2174/138161206778194088 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employed in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, and prediction, to monitoring of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Food Allergy
Current Pharmaceutical Design Efficacy and Safety of Nonopioid Analgesics in Perioperative Pain Control
Current Drug Safety Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics
Current Drug Targets In Silico-In Vitro Screening of Protein-Protein Interactions: Towards the Next Generation of Therapeutics
Current Pharmaceutical Biotechnology Cytokine and Nitric Oxide Production Following Severe Envenomation
Current Drug Targets - Inflammation & Allergy An Update on Nonsteroidal Anti-Inflammatory Drug-Induced Urticaria
Endocrine, Metabolic & Immune Disorders - Drug Targets Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Update on Medical and Surgical Management of Intracerebral Hemorrhage
Reviews on Recent Clinical Trials Recent Advances in Enzyme Inhibition: A Pharmacological Review
Current Enzyme Inhibition Hypersensitivity to Antineoplastic Agents
Current Pharmaceutical Design Small Peptides as Modulators of Serine Proteases
Current Medicinal Chemistry Hymenoptera Venom Proteins and Peptides for Diagnosis and Treatment of Venom Allergic Patients
Inflammation & Allergy - Drug Targets (Discontinued) Malaria in Children - Prevention and Management
Infectious Disorders - Drug Targets Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Review of Newer Anticoagulants and Anti-platelet Agents in Acute Coronary Syndrome and Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Efficacy and Safety of H1-Antihistamines: An Update
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Current Strategies to Achieve Further Cardiac and Renal Protection through Enhanced Renin-Angiotensin-Aldosterone System Inhibition
Reviews on Recent Clinical Trials Adamantane – A Lead Structure for Drugs in Clinical Practice
Current Medicinal Chemistry The Validity of Chemical Analytical Methods by the Example of the Heparin Product Recall
Current Pharmaceutical Analysis